Effects of oral duloxetine on reduction of symptoms of peripheral neuropathy
Phase 3
Recruiting
- Conditions
- Chemotherapy-induced peripheral neuropathy.
- Registration Number
- IRCT20110514006480N16
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Patients under treatment with neurotoxic chemotherapy drugs, Which have symptoms of peripheral neuropathy
Normal blood calcium and magnesium levels
Exclusion Criteria
Having diabetes and other causes of peripheral neuropathy
History of severe hypersensitivity to duloxetine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean scores of peripheral neuropathy symptoms in LQ-CIPN20 questionnaire. Timepoint: Before the intervention, 4 week after treatment with duloxetine. Method of measurement: LQ-CIPN20 questionnaire.
- Secondary Outcome Measures
Name Time Method